Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease

THR-687, a potent small molecule integrin antagonist, holds promise as a therapeutic approach for back-of-the-eye vascular pathologies

Vermassen E , Hu TT, Van Hove I, Vanhove M, Porcu M, Jonckx B, Barbeaux P, Feyen JHM. THR-687, a potent small molecule integrin antagonist, holds promise as a therapeutic approach for back-of-the-eye vascular pathologies. 2018

Publication date: 
June, 2018